Lyft, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Lyft, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.32B | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $5.79B | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | $4.40B | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | $4.10B | Feb 14, 2025 |
| FY2021 | Dec 31, 2021 | $969.93M | Apr 29, 2022 |
| FY2021 | Sep 30, 2021 | $864.41M | Apr 29, 2022 |
| FY2021 | Jun 30, 2021 | $765.03M | Apr 29, 2022 |
| FY2021 | Mar 31, 2021 | $608.96M | Apr 29, 2022 |
| FY2022 | Dec 31, 2020 | $2.36B | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $3.62B | Apr 29, 2022 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.90B | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $5.37B | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | $4.12B | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | $3.81B | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $2.96B | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $2.21B | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $3.47B | Apr 29, 2022 |
| FY2020 | Dec 31, 2018 | $2.11B | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $1.06B | Feb 28, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.84B | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $22.78M | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | ($340.32M) | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | ($1.58B) | Feb 14, 2025 |
| FY2021 | Dec 31, 2021 | ($283.17M) | Apr 29, 2022 |
| FY2021 | Sep 30, 2021 | ($99.71M) | Apr 29, 2022 |
| FY2021 | Jun 30, 2021 | ($251.92M) | Apr 29, 2022 |
| FY2021 | Mar 31, 2021 | ($427.34M) | Apr 29, 2022 |
| FY2022 | Dec 31, 2020 | ($1.75B) | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | ($2.60B) | Apr 29, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($188.37M) | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | ($118.91M) | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | ($475.60M) | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | ($1.46B) | Feb 14, 2025 |
| FY2021 | Dec 31, 2021 | ($273.62M) | Apr 29, 2022 |
| FY2021 | Sep 30, 2021 | ($205.04M) | Apr 29, 2022 |
| FY2021 | Jun 30, 2021 | ($240.12M) | Apr 29, 2022 |
| FY2021 | Mar 31, 2021 | ($416.44M) | Apr 29, 2022 |
| FY2022 | Dec 31, 2020 | ($1.81B) | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | ($2.70B) | Apr 29, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $451.42M | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $397.07M | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | $555.92M | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | $856.78M | Feb 14, 2025 |
| FY2021 | Dec 31, 2021 | $195.00M | Apr 29, 2022 |
| FY2021 | Sep 30, 2021 | $226.69M | Apr 29, 2022 |
| FY2021 | Jun 30, 2021 | $252.04M | Apr 29, 2022 |
| FY2021 | Mar 31, 2021 | $238.22M | Apr 29, 2022 |
| FY2022 | Dec 31, 2020 | $909.13M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $1.51B | Apr 29, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.17B | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $849.74M | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | ($98.24M) | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | ($237.29M) | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | ($101.72M) | Feb 20, 2024 |
| FY2021 | Sep 30, 2021 | ($75.50M) | Apr 29, 2022 |
| FY2022 | Dec 31, 2020 | ($1.38B) | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | ($105.70M) | Apr 29, 2022 |
| FY2020 | Dec 31, 2018 | ($280.67M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | ($393.53M) | Feb 28, 2020 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.03B | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $5.44B | Feb 11, 2026 |
| FY2024 | Dec 31, 2023 | $4.56B | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | $4.56B | Feb 20, 2024 |
| FY2022 | Dec 31, 2021 | $4.77B | Feb 27, 2023 |
| FY2021 | Sep 30, 2021 | $4.82B | Apr 29, 2022 |
| FY2021 | Dec 31, 2020 | $4.68B | Apr 29, 2022 |
| FY2020 | Dec 31, 2019 | $5.69B | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $3.76B | Feb 28, 2020 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.76B | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $4.67B | Feb 11, 2026 |
| FY2024 | Dec 31, 2023 | $4.02B | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | $4.17B | Feb 20, 2024 |
| FY2022 | Dec 31, 2021 | $3.43B | Feb 27, 2023 |
| FY2021 | Sep 30, 2021 | $3.37B | Apr 29, 2022 |
| FY2021 | Dec 31, 2020 | $3.00B | Apr 29, 2022 |
| FY2020 | Dec 31, 2019 | $2.84B | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $1.48B | Feb 28, 2020 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.27B | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $767.02M | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | $541.52M | Feb 11, 2026 |
| FY2025 | Dec 31, 2022 | $388.67M | Feb 11, 2026 |
| FY2024 | Dec 31, 2021 | $1.34B | Feb 14, 2025 |
| FY2021 | Sep 30, 2021 | $1.46B | Apr 29, 2022 |
| FY2021 | Jun 30, 2021 | $1.36B | Apr 29, 2022 |
| FY2021 | Mar 31, 2021 | $1.41B | Apr 29, 2022 |
| FY2023 | Dec 31, 2020 | $1.68B | Feb 20, 2024 |
| FY2022 | Dec 31, 2019 | $2.85B | Feb 27, 2023 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $439.75M | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $251.38M | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | $257.79M | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | $261.58M | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $180.52M | Feb 20, 2024 |
| FY2021 | Sep 30, 2021 | $180.52M | Apr 29, 2022 |
| FY2022 | Dec 31, 2020 | $182.69M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $158.73M | Apr 29, 2022 |
| FY2020 | Dec 31, 2018 | $152.09M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $0 | Feb 28, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($7.41B) | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | ($10.26B) | Feb 11, 2026 |
| FY2024 | Dec 31, 2023 | ($10.28B) | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | ($9.94B) | Feb 20, 2024 |
| FY2022 | Dec 31, 2021 | ($8.36B) | Feb 27, 2023 |
| FY2021 | Sep 30, 2021 | ($8.08B) | Apr 29, 2022 |
| FY2021 | Dec 31, 2020 | ($7.30B) | Apr 29, 2022 |
| FY2020 | Dec 31, 2019 | ($5.55B) | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | ($2.95B) | Feb 28, 2020 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.13B | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $759.32M | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | $558.64M | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | $281.09M | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $457.33M | Feb 20, 2024 |
| FY2021 | Sep 30, 2021 | $728.38M | Apr 29, 2022 |
| FY2022 | Dec 31, 2020 | $319.73M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $358.32M | Apr 29, 2022 |
| FY2020 | Dec 31, 2018 | $517.69M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $1.11B | Feb 28, 2020 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.05B | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | $995.05M | Feb 11, 2026 |
| FY2024 | Dec 31, 2023 | $865.16M | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | $839.49M | Feb 20, 2024 |
| FY2022 | Dec 31, 2021 | $711.44M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $680.00M | Apr 29, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 6 | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | (4) | Feb 14, 2025 |
| FY2021 | Dec 31, 2021 | 0 | Apr 29, 2022 |
| FY2021 | Sep 30, 2021 | 0 | Apr 29, 2022 |
| FY2021 | Jun 30, 2021 | 0 | Apr 29, 2022 |
| FY2021 | Mar 31, 2021 | (1) | Apr 29, 2022 |
| FY2022 | Dec 31, 2020 | (5) | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | (11) | Apr 29, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 6 | Feb 11, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 11, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | (4) | Feb 14, 2025 |
| FY2021 | Dec 31, 2021 | 0 | Apr 29, 2022 |
| FY2021 | Sep 30, 2021 | 0 | Apr 29, 2022 |
| FY2021 | Jun 30, 2021 | 0 | Apr 29, 2022 |
| FY2021 | Mar 31, 2021 | (1) | Apr 29, 2022 |
| FY2022 | Dec 31, 2020 | (5) | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | (11) | Apr 29, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | 0 | Feb 28, 2020 |
| FY2019 | Dec 31, 2018 | 22.44M | Feb 28, 2020 |